Our current study supports this conclusion, because the p53-null human prostate cancer PC3 cell line was also proven sensitive to 400 nM FP treatment, as revealed for the LNCaP and DU145 cells (Figures S10 and 1). This evidence concerns the gene TP53 and prostate carcinoma.